The objective of this research was to compare the growth performance, incidence of prolapse and mortality, carcass characteristics, blood hormone concentration, and N balance of lambs implanted with increasing dosages of zeranol. One hundred forty-four crossbred lambs (29.6 ± 4.9 kg) were used in a completely random design and placed into 16 feedlot pens (4 pens/treatment) for a 116 d fi nishing study. Lambs were fed an 84.7% corn and 15.3% market lamb pellet (DM basis) diet ad libitum. Treatments were 0, 12, 24, and 36 mg zeranol (Ralgro; Schering-Plough), and lambs were implanted in the ear according to treatment on d 0. Lambs were weighed. Thirty lambs (67.6 ± 3.4 kg) and 96 lambs (65.8 ± 5.1 kg) were harvested on d 84 and d 118, respectively. Carcass data were collected 24 h after chill. Blood samples were collected on d 0, 28, 56, 70, 82, 99, and 116 from 64 lambs (29.6 ± 2.1 kg) in the feedlot study (subsample of 4 lambs per pen) and analyzed for thyroxine, triiodothyronine, and IGF-I. A second study was conducted to compare effects of 0, 12, 24, or 36 mg zeranol on N balance in 16 crossbred lambs (34.8 ± 2.1 kg). There were no differences among treatments for BW, ADG, DMI, and G:F (P > 0.05) in the feedlot study. However, there was a linear increase for incidence of prolapse (P = 0.006; 2.78, 5.55, 24.98, and 27.75%, respectively) and mortality (P = 0.005; 0.00, 5.55, 11.10, and 13.88%, respectively) as zeranol dosage increased. Carcass characteristics, blood hormone concentrations, and N balance were not affected by treatment (P > 0.05). These results indicate zeranol increases incidence of prolapse and mortality without increasing growth performance.
INTRODUCTION
Zeranol improves growth in lambs implanted with 12 mg once (Field et al., 1993; Stultz et al., 2001; Salisbury et al., 2007) or multiple times (Nold et al., 1992; Hufstedler et al., 1996) . However, zeranol has also been implicated in an increased incidence of prolapse (Arnsperger et al., 1976; Salisbury et al., 2007) , resulting in decreased use of zeranol in the United States lamb feeding industry (Lupton, 2008) . Domínguez et al. (2010) reported greater BW gain in lambs implanted with 24 mg zeranol compared with lambs implanted with 12 mg zeranol but did not report the incidence of prolapse. Eckerman et al. (2011) reported conventionally raised lambs implanted with 36 mg zeranol had greater growth compared with nonimplanted, naturally raised lambs but also found conventional lambs had greater incidence of prolapse and mortality. Moreover, the effects of zeranol on N balance and blood hormones have yet to be elucidated. An accurate assessment of how zeranol affects N balance and hormones involved in growth, such as triiodothyronine (T3), thyroxine (T4), and IGF-I, may foster research to defi ne the mechanism of action through which zeranol works. Triiodothyronine and T4 have also been shown to be involved with the regulation of IGF-I (Thissen et al., 1994) . One of the primary effect of IGF-I is stimulation of cartilage growth, subsequently causing linear growth of the skeleton (Bolander, 1994) . Zeranol increases GH concentrations (Borger et al., 1973; Wiggins et al., 1976; Gopinath and Kitts, 1984) and in turn greater IGF-I (Clemmons et al., 1987) . The objective for this study was to determine effects of increasing dosages of zeranol on lamb growth performance, incidence of prolapse and mortality, carcass characteristics, blood hormone concentration, and N balance.
MATERIALS AND METHODS
All animal care and handling procedures were approved by the North Dakota State University Animal Care and Use Committee before the initiation of the research (protocol number A10051).
Feedlot and Hormone Concentration Study
Animals and Treatment. At 2 wk of age, tails were docked, males were castrated, and all lambs were vaccinated for Clostridium perfringens types C and D as well as for tetanus (CD-T; Bar Vac CD/T; Boehringer Ingelheim, Ridgefi eld, CT). Lambs were adapted to a 84.7% corn and 15.3% commercial market lamb pellet diet (DM basis; Table 1 ) from a 100% creep pellet diet (16% CP and 3.5% crude fat) after weaning. Lambs were vaccinated with CD-T again at 60 d of age (weaning) and d -1 of the study. One hundred fortyfour spring-born crossbred lambs (western white-faced Rambouillet × Suffolk) were stratifi ed by BW (initial BW 29.6 ± 4.9 kg; approximate age = 100 d) and sex (63 wethers and 81 ewes) and randomly assigned to 1 of 16 outdoor pens (9 lambs/pen; 14 m 2 /lamb). Pens were assigned randomly to 1 of 4 treatments, with pen serving as the experimental unit (n = 4 pens/treatment). Treatments were 0, 12, 24, or 36 mg/lamb zeranol implant. Zeranol is no longer available commercially in a 12 mg dosage; therefore, treatments were modifi ed from the commercially available 36 mg cattle dosage by removing the appropriate number of 12 mg pellets. Ears were palpated after administration of implant to ensure pellets were present and not crushed. Treatments were applied in a completely random design to evaluate the outlined objectives. A subset of 64 lambs (29.6 ± 2.1 kg BW) were randomly selected from the feedlot pens and stratifi ed by BW and sex to conduct a blood hormone study. Two wethers and 2 ewes were selected from each pen on d 0 and were used for blood collections throughout the trial.
Lambs receiving zeranol were subcutaneously implanted in the ear with zeranol (Ralgro, ScheringPlough Animal Health Corp., Union, NJ) according to treatment on d 0; the other lambs were not implanted. All feeds were provided whole, mixed in a grinder-mixer (Gehl Mix-All, Model 170, Gehl, West Bend, WI), and offered ad libitum via bulk feeders (54-cm bunk space/ lamb). Lambs had continuous access to clean, fresh water and shade. Study diets were balanced to be equal to or greater than CP and energy (NE) requirements (NRC, 2007) . The rations were formulated to have a minimum Ca:P ratio of 2:1. All lambs received the same diet: 84.7% whole corn and 15.3% market lamb pellet (DM basis; Table 1 ). Feeders were checked daily and cleaned of contaminated feed (e.g., fecal contamination, wet feed caused by precipitation). Lambs were observed daily to monitor health. Lambs were treated with antibiotics as necessary. Five lambs were treated for morbidity not related to prolapse (1, 2, and 2 for treatments 0, 24, and 36, respectively) and were not removed from the study. Lambs that rectally or vaginally prolapsed were treated through the use of sutures, oxytetracycline, and general antibiotics and were not removed from the study.
Data Collection Procedures. The study was divided into 4 periods, consisting of 28, 28, 26, and 34 d, respectively. Period BW were used to assist in evaluation of lambs for morbidity. Lambs were weighed on 2 consecutive d at initiation (d -1 and 0) of the trial and after the third and fourth period; single day weights were taken after periods 1 and 2. Bulk feeders were emptied at the end of each period and orts weighed, sampled (approximately 2.0 kg), and dried at 55°C for 48 h to determine DM. These data were used to calculate DMI. Ration and feed ingredient samples (approximately 2.0 kg) were collected for every period to determine ration nutrient composition and dried at 55°C for 48 h to determine DM and to calculate DMI. Dried samples were ground using a Wiley mill (Arthur H. Thomas Co., Philadelphia, PA) to pass a 2-mm screen. Samples were analyzed for DM, ash (method 942.05; AOAC Int., 2010) , N (method 2001.11; AOAC Int., 2010) using a Kjeltec Auto 1030 Analyzer (Tecato AB, Höganäs, Sweden), NDF (Van Soest et al., 1991) as modifi ed by Ankom Technology (Fairport, NY) using an Ankom 200 Fiber Analyzer without sodium sulfi te, with amylase, and without ash corrections as sequentials, and ADF (Goering and Van Soest, 1970) . After 2-d BW on d 84 and 118, all lambs greater than 56 kg were harvested at Iowa Lamb Corporation (Hawarden, IA). Thirty lambs (67.6 ± 3.4 kg; 10, 7, 6, and 7 lambs for treatments 0, 12, 24, and 36, respectively) were harvested on d 84. Ninety-six lambs (65.8 ± 5.1 kg; 22, 25, 25, and 24 lambs for treatments 0, 12, 24, and 36, respectively) were harvested on d 118. Data for lambs too light for shipment to commercial abattoir (4, 2, 1, and 0 lambs for 0-, 12-, 24-, and 36-mg treatments, respectively) were included in growth performance analyses but not carcass analyses. The total number of lambs harvested was 32, 32, 31, and 31 for treatments 0, 12, 24, and 36, respectively. Average daily gain was calculated for each lamb for each period and averaged to obtain ADG over the course of the study for each pen.
Carcass data collected included HCW, leg score, conformation score, fat depth (over the 12th rib), body wall thickness, ribeye area, fl ank streaking, quality grade, and yield grade. Leg score, conformation score, and quality grade were scored on a scale of 1 to 15 (1 = cull to 15 = high prime). Flank streaking was assigned, with score of 100 to 199 = practically devoid, 200 to 299 = traces, 300 to 399 = slight, 400 to 499 = small, and 500 to 599 = modest. Percentage of boneless, closely trimmed retail cuts was calculated using this equation: [49.936 -(0.0848 × 2.205 × HCW) -(4.376 × 0.3937 × fat depth) -(3.53 × 0.3937 × body wall thickness) + (2.456 × 0.155 × ribeye area)], in which HCW is measured in kilograms, fat depth and body wall thickness are measured in centimeters, and ribeye area is measured in square centimeters, from Savell and Smith (2000) . Carcass data were collected by trained personnel after a 24-h chill (temperature <2ºC and humidity near 100%).
Blood samples (10 mL) were collected via jugular venipuncture to observe changes in blood hormones across treatments on weigh days as well as 2 additional time points during the time period when payout of implants was expected to be maximized (d 0, 28, 56, 70, 82, 99, and 116) via serum separator vaccutainers (catalog number 14219-242; VWR International, Radnor, PA). Vaccutainers were placed on ice for transport to lab and then stored in a cooler (-2 degrees C) for 2 hours. Vaccutainers were centrifuged (3,640 × g, 15 degrees C, 20 min) and serum was harvested and stored (-20°C). Serum samples were analyzed for T3 and T4 by chemiluminescence immunoassay using the Immulite 1000 system (Siemens Healthcare Diagnostics Inc., Los Angeles, CA) using commercial kits (catalog numbers LKT31 and LKT41, respectively; Siemens Healthcare Diagnostics Inc.) as instructed by manufacturer. Within each assay, lesser, medium, and greater T3 and T4 pools were assayed in duplicate. Twenty-fi ve-microliter and 15-μL serum samples were assayed in duplicate for T3 and T4, respectively. The intra-assay CV were 4.33 and 4.07% for T3 and T4, respectively, and the interassay CV were 6.89 and 6.63% for T3 and T4, respectively. In addition, the T4:T3 ratio was calculated. Serum IGF-I was quantifi ed using the double antibody RIA (Berrie et al., 1995) at New Mexico State University, Las Cruces, NM. The intra-assay and interassay CV for IGF-1 were 12.8 and 13.8% respectively.
Statistical Analyses. All data from the feedlot and hormone concentration study were analyzed with pen serving as experimental unit. Lamb performance data were analyzed as a completely random design using the MIXED procedure (SAS Inst. Inc., Cary, NC). Incidence of prolapse and mortality were measured as a percent of lambs per pen. Carcass data were analyzed as a randomized design, with missing data points from underweight lambs not included in the data set. Lamb blood hormone data were averaged within pen and analyzed as a completely randomized design using the MIXED procedure of SAS. Repeated measures was used to analyze day effects for T3, T4, T4:T3, and IGF-1. The model included treatment, day, and day × treatment interaction. The covariance structure used was Compound Symmetry. Simple, First Order Autoregressive, First Order Ante Dependence, and Unstructured were also tested, but Compound Symmetry was the best fi t. When signifi cant F-tests were observed (P ≤ 0.05), preplanned comparison of linear, quadratic, and cubic contrasts were used to partition treatment effects with a critical P-value of ≤0.05.
Nitrogen Balance Study
Animals and Treatments. The objective of this study was to determine the infl uence of increasing dosages of zeranol on lamb N intake, N excretion, N balance, and serum urea-N concentration. Sixteen crossbred (western white-faced Rambouillet × Suffolk) wethers (34.9 ± 2.1 kg; approximate age = 100 d) were used in a completely random design. Wethers were weighed on d 0 and 1, stratifi ed by weight, and allotted randomly to treatments (n = 4 wethers/treatment) of 0, 12, 24 or 36 mg zeranol (Ralgro; Schering-Plough Animal Health Corp.) implants. Lambs were subcutaneously implanted with zeranol according to treatment and assigned randomly to individual metabolism crates on d 1. Wethers were housed in an enclosed room with lighting from approximately 0730 to 2000 h. Lambs were adapted to diets and processed as outlined in the previous study but were also dewormed with ivermectin (Ivomec, Merial Limited, Duluth, GA). Diets were the same as outlined previously (Table 1) . Rations were provided daily at 0830 h at 130% of the average daily intake for the previous 5 d. Feed refusals from the previous day were determined before feeding. Water troughs were cleaned and refi lled daily after feeding.
Data Collection Procedures. The experimental period was 21 d. Dry matter intake was determined on d 14 to 20. Additionally, samples of corn, pellets, and ration were collected on d 14 to 20 and dried at 55°C for 48 h to determine DM. Orts were collected on d 15 to 21 and dried at 55°C for 48 h. Wethers were fi tted with fecal collection bags on d 11. Total fecal and urine output were collected on d 15 to 21. A subsample of each daily fecal sample (7.5% of total, wet basis) was dried at 55°C for 96 h for calculation of fecal DM. Urine was collected via stainless steel funnel beneath the lamb, with total urine output collected. Suffi cient 6 N HCL (100 mL) was added daily to urinals to maintain urine pH < 3. Total daily urine output was recorded and urine was composited daily by wether (10% of total; wet basis) and stored at 4°C. Approximately 288 g of urine were collected from each urine subsample and stored at 4°C. On d 15 to 21, 10 mL of blood were collected via jugular venipuncture 4 h after feeding using vaccutainers (catalog number VT6430; VWR International). Blood was cooled at 4°C for 2 h and centrifuged (3,640 × g, 15 degrees C, 20 min), and serum was harvested and stored (-20°C) .
Dried fecal samples were ground through a Wiley mill (2-mm screen) and composited by lamb. Daily samples of corn, pellets, and ration were composited for the collection period, and orts were composited by lamb on an equal weight basis (20%; as-fed basis). Feed, orts, and fecal samples were analyzed for DM, ash, NDF, and ADF as described previously. Feed, orts, fecal, and urine samples were analyzed for N as described previously. Concentration of N in feed, orts, fecal, and urine samples was used to calculate daily N intake and excretion from feed, ort, feces, and urine weights. Nitrogen excretion (fecal N + urinary N) was subtracted from N intake (feed N -ort N) to calculate N balance (g N/kg BW basis). Serum samples were analyzed for urea-N using the Sigma Diagnostics Procedure 640 (Sigma Chemical Co., St. Louis, MO) and an ultraviolet-visible spectroscopy spectrophotometer (DU 800 Spectrophotometer, Beckman Coulter, Brea, CA).
Statistical Analysis. Lamb N balance data were analyzed as a randomized design using the MIXED procedure of SAS with animal serving as experimental unit. Repeated measures was used to analyze day effect for serum urea-N. The model included treatment, day, and day × treatment interaction. The covariance structure used was Autoregressive (1). Other structures were tested but Autoregressive (1) was the best fi t. When a signifi cant F-test was observed (P ≤ 0.05), preplanned comparison of linear, quadratic, and cubic contrasts were used to partition treatment effects with a critical P-value of ≤0.05.
RESULTS AND DISCUSSION
No quadratic or cubic effects were observed (P ≥ 0.09); therefore, only the protected F-test and P-value for linear effects are reported in the text.
Feedlot and Hormone Concentration Study
Growth Performance. Results for feedlot lamb growth, carcass characteristics, and health are reported in Table 2 . No differences were observed among treatments for fi nal BW or ADG (P > 0.05). Similarly, feed intake and G:F were not different among treatments (P > 0.05). The results of the feedlot study agree with some of the previous research that found no effect of zeranol implant on ADG (Wiggins et al., 1976; Nold et al., 1992; Field et al., 1993) or feed effi ciency (Wiggins et al., 1976) . However, the majority of the research indicates implanting feedlot lambs with 12 mg zeranol increases ADG (Hutcheson et al., 1992; Stultz et al., 2001; Salisbury et al., 2007) and G:F (Olivares and Hallford, 1990; Field et al., 1993; Stultz et al., 2001) . Previous research also indicates G:F can be improved by implanting lambs twice with 12 mg zeranol (Nold et al., 1992) , and both G:F and ADG can be improved by implanting lambs with 12 mg of zeranol 3 or more times (Hufstedler et al., 1996) . Minimal research is available comparing different dosages of zeranol implants on growth performance although Domínguez et al. (2010) reported lambs implanted with 24 mg zeranol had increased ADG and G:F compared with lambs implanted with 12 mg zeranol or not implanted. In the present study, lambs suffering from prolapse often went off feed, which could have resulted in decreased ADG, G:F, and BW compared with nonprolapsed lambs in the same treatment. Therefore, morbidity resulting from incidence of prolapse may have caused the lack of differences across treatments.
Prolapse and Mortality. As zeranol dose increased, prolapse incidence increased linearly (Table 2 ; P = 0.006; 2.78, 5.55, 24.98, and 27.75%, respectively). Over the course of the study, 14 ewes prolapsed vaginally, rectally, or both (3, 7, and 4, respectively) and 8 wethers had rectal prolapses. Accordingly, mortality also increased linearly (P = 0.005; 0.00, 5.55, 11.10, and 13.88%, respectively). The total death loss per pen was as follows: 0 mg = 0 pens with mortality, 12 mg = 1 pen with 1 death, 24 mg = 2 pens with 1 death and 1 pen with 2 deaths, and 36 mg = 2 pens with 1 death and 2 pens with 2 deaths. Few studies (Arnsperger et al., 1976; Salisbury et al., 2007; Sluiter et al., 2007) have previously reported complications of prolapse resulting from zeranol implants, and no studies have reported problems with mortality. Studies examining the use of 2, 3, or more implants did not report any incidences of prolapse. The fi nishing diets used by Salisbury et al. (2007) , Sluiter et al. (2007) , and the present study were high in concentrate (>70%). Arnsperger et al. (1976) noted that lambs implanted with zeranol and raised on pasture had a decreased rate of prolapse than lambs implanted and raised on a growing ration. Additionally, no differences were observed in the rate of prolapse between implanted and nonimplanted lambs raised on pasture. A possible explanation for the difference in prolapse incidence rates between concentrate fed vs. pasture fed lambs may be the combination of zeranol, causing uterine muscle contraction (functioning as an estrogen agonist) and high concentrate rations causing increased fat deposition around the tail, thereby increasing the incidence of vaginal prolapse (Thornsberry, 1993; Salisbury et al., 2007) . As such, high concentrate diets could be implicated in contributing to increased incidence of prolapse. However, the high incidence of prolapse in the study by Arnsperger et al. (1976) did not appear to hinder the growth performance of the lambs.
Carcass Characteristics. There were no differences (Table 2 ; P > 0.05) for carcass characteristics in lambs implanted with increasing dosages of zeranol in the present study. The effects of zeranol on lamb carcass characteristics in previous research have been inconsistent. Wilson et al. (1972) reported greater carcass weight in implanted lambs, but no other carcass characteristics were different between implanted and nonimplanted lambs. Conversely, Stultz et al. (2001) 2 P-value for linear, quadratic, and cubic effects of increasing dosage of zeranol.
3 n = 4.
4 Leg score, conformation score, and quality grade: 1 = cull to 15 = high prime.
5 Adjusted fat depth and yield grades. reported lambs implanted with zeranol had decreased ribeye area and carcass weight compared with lambs that were not implanted. Wiggins et al (1979) found implanted lambs had greater gastrointestinal tract weight, which subsequently resulted in decreased dressing percentage. Lambs implanted with zeranol can also have greater fat depth (Field et al., 1993) . However, the majority of research indicates no effect of zeranol on carcass characteristics (Wiggins et al. 1976; Olivares and Hallford, 1990; Sluiter et al., 2007) .
No research analyzing the effects of increasing doses of zeranol on carcass characteristics are known to the authors. However, reimplanting lambs has been shown to alter carcass characteristics, albeit inconsistently. Lambs implanted twice (d 0 and 56) or at 30 d intervals have been reported to have greater dressing percentage (Hufstedler et al., 1996; Salisbury et al., 2007) whereas lambs implanted twice have also been reported to have decreased dressing percentage (Hutcheson et al., 1992) . Twice-implanted lambs also have increased leg score (Hutcheson et al., 1992; Nold et al., 1992) . Hufstedler et al. (1996) implanted lambs at 30 d intervals (total of 3 or 5 implants) and observed greater percentage of kidney and pelvic fat and carcass maturity compared with nonimplanted lambs. Conversely, Field et al. (1993) harvested lambs implanted twice with zeranol and found no differences in carcass characteristics. The aforementioned research would suggest that although zeranol could potentially alter carcass characteristics, the effects are inconsistent.
As the carcass data and livestock performance data are compared, there is an interesting trend regarding ADG, fi nal BW, and the number of lambs ready for harvest at the end of the trial. Although ADG and fi nal BW are not affected by treatment, there was a numerical trend for the number of lambs too light for carcass data collection (4, 2, 1, and 0 for the 1-, 12-, 24-, and 36-mg treatments, respectively). Although these values are a subsample of the experimental unit (pen) and therefore not testable statistically, it does indicate the possibility of a trend for increased BW gain through the use zeranol implants. The potential reason for not observing an increase in ADG and fi nal BW but observing an increase in lambs ready for harvest as zeranol dosage increased could be related to prolapse and mortality. As the dosage of zeranol increased, prolapse and mortality increased. Individual lamb BW likely suffered as a result of prolapse and mortality. However, for the lambs not suffering from prolapse, individual BW gain was likely enhanced, resulting in the unaffected lambs having individual BW that contributed to the average BW of the experimental unit, resulting in performance that was similar across treatments. However, these remaining lambs in the increasing dosage of zeranol treatments were in fact heavier than their contemporaries in the low dosage treatments, resulting in fewer light BW lambs. Additionally, some effects on carcass data may have been detected if the light weight lambs would have been harvested; due to logistical constraints (distance to the abattoir), feeding the remaining light weight lambs to an acceptable harvest weight was not possible. The authors felt the current analysis provides a consistent carcass evaluation of lambs that were ready for harvest.
Triiodthyronine, Thyroxine, and IGF-I. Results for the effects of increasing dosages of zeranol implants on lamb T3, T4, and IGF-I concentrations and T4:T3 ratios are reported in Table 3 . No treatment × day interactions (P > 0.05) were observed. An effect of day was observed (P < 0.001), with T3 decreasing and T4, T4:T3, and IGF-I increasing as time progressed from d 0 to 116 (data not shown). However, to aid interpretation of the results, means are presented for the treatment effects. No differences were observed among treatments for T3, T4, and IGF-I concentrations or T4:T3 ratio (P > 0.05). The mode of action by which zeranol improves growth is as of yet unknown, but it may involve the effects of zeranol on T3, T4, and IGF-I. Triiodothyronine and T4 are involved in the regulation of IGF-I (Thissen et al., 1994) . One of the primary effects of IGF-I is stimulation of cartilage growth, subsequently causing linear growth of the skeleton (Bolander, 1994) . Zeranol increases GH concentrations (Borger et al., 1973; Wiggins et al., 1976; Gopinath and Kitts, 1984) , and in turn, increases in GH cause increases in IGF-I (Clemmons et al., 1987) . Therefore, literature suggests lambs implanted with zeranol should have increased growth, which could be caused by increased IGF-I concentrations. Current research has been inconclusive on the effects of zeranol on T3 and T4. No differences in T4 concentrations between implanted and nonimplanted steers were observed by Price et al. (1983) and Gopinath and Kitts (1984) . Gray et al (1986) found bulls implanted with 36 mg zeranol at birth had decreased T4 concentrations at 13.9 mo of age compared with nonimplanted bulls although no difference in T4 concentrations were observed overall. Doornenbal et al. (1987) observed no differences in T3 and T4 concentrations when comparing nonimplanted bulls with bulls implanted 3 or 4 times. Later research found zeranol decreased T3 concentrations in implanted steers compared with nonimplanted steers, with no effect on T4 (Williams et al., 1991) . Wiggins et al (1979) reported that lambs implanted with 12 mg zeranol had decreased T4 concentrations compared with nonimplanted lambs on average but were only signifi cantly decreased on d 42 after implantation. The results of the present study found no difference in T3 and T4 concentrations across treatments, suggesting the mode of action by which zeranol improves lamb growth is not related to T3 and T4. However, as there were no differences in growth across treatments, this cannot be confi rmed by the present study. Hammond et al. (1990) suggested IGF-I concentration is related to plasma thyroid hormone concentrations as well as nutritional status. Further research has shown steer ADG is correlated with plasma concentrations of IGF-I (Ellenberger et al., 1989; Hersom et al., 2004) . Hufstedler et al. (1996) observed lambs implanted with 12 mg of zeranol every 30 d had greater GH and IGF-I concentrations compared with nonimplanted lambs. Thomas et al. (2000) observed a time × treatment interaction, with lambs implanted with zeranol having greater GH and IGF-I compared with nonimplanted lambs in the fi rst and last 45 d of the study; implanted lambs also had greater GH and IGF-I concentrations overall. However, no differences were observed between treatments for IGF-I concentrations in the present study. Hammond et al. (1990) suggested IGF-I concentration is related to nutritional status. As such, the increased incidence of prolapse causing lambs to go off feed may have affected the IGF-I concentrations in lambs implanted with increased dosages zeranol.
Nitrogen Balance Study
There were no differences among treatments for N intake, N excretion, N balance, or serum urea-N (P > 0.05; Table 4 ). Additionally, no day or treatment × day interactions were observed (P = 0.57 and 0.96, respectively) for serum urea-N. Research analyzing N balance in ruminants implanted with zeranol is limited, but the research available primarily indicates zeranol affects N metabolism. Hufstedler and Greene (1995) observed decreased urinary N excretion in lambs implanted with 12 mg zeranol compared with controls, but differences in N retention and absorption were not detected. Griffi ths (1982) observed greater N retention in steers implanted with 36 mg resorcylic acid lactone. A 40 d comparative slaughter study by Sharp and Dyer (1971) also observed greater N retention in lambs implanted with 12 mg zeranol compared with nonimplanted lambs. VanderWal et al. (1975) performed several studies analyzing N retention and found 36 mg zeranol implants in calves increases N retention, implanting calves with 72 mg zeranol did not improve N retention, and N retention in calves implanted with 72 mg zeranol was not different from the nonimplanted controls. These results could indicate that implanting animals with increasing dosages relative to BW decreases the effects of zeranol on N retention. The only study able to detect a difference in N balance between implanted and nonimplanted lambs was the 40 d comparative slaughter study of Sharp and Dyer (1971) . This may suggest that 7 d collection periods are not comprehensive enough to detect the slight increases in protein accretion caused by zeranol. Accordingly, no differences were found for N balance across treatments in the present study. Despite increased incidence of prolapse and mortality in lambs treated with zeranol in the feedlot study, there were no incidents of prolapse or mortality during the course of the N balance study.
Lambs implanted with increased dosages of zeranol had no difference in growth performance, carcass characteristics, blood hormone concentrations, or N balance. However, as zeranol dose increased, prolapse incidence and mortality increased linearly. Subsequently, increased zeranol doses are not recommended for use in feedlot lambs on high concentrate rations. However, the rate of prolapse in implanted lambs may be exacerbated by the high concentrate ration used in the present study. Increased zeranol doses may be effective in improving growth performance in lambs fed lower concentrate rations or on pasture; however, this was not explored in our studies. Triiodothyronine, T4, and IGF-I were expected to be related to increased growth rate, but as with growth, there were no differences across treatments for hormone concentrations. Additionally, there were no differences across treatments for N intake, N excretion, N balance, or serum urea-N concentration.
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